Mn(II)-Tagged DOTA-Modified Sugar-Based Biopolymers as Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging
Pharmaceutics · 27.04.2026 · 18 (5) · 530
DOI: 10.3390/pharmaceutics18050530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.04.2026. Verfasst von Irena Pashkunova-Martic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Imaging and Image-Guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna & G…. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FWF Austrian Science Fund.
Abstract (Originalsprache)
Background
Paramagnetic manganese (Mn(II)) has emerged as a promising alternative to gadolinium-based contrast agents (GBCAs) due to its favorable magnetic properties. Despite extensive research, no Mn-based agent has yet achieved clinical translation. Because free Mn(II) is toxic, macromolecular complexes incorporating stable macrocyclic DOTA chelators conjugated to polysaccharides may enhance coordination stability and improve the safety profile of Mn(II)-based contrast agents.
Methods
Two chemical routes, maleimide- and ester-mediated, were evaluated for covalent coupling of DOTA-based macrocyclic ligands to the backbone of selected poly- and oligosaccharides. Subsequently, DOTA-modified carboxymethyldextran, aminodextran, and chitosan oligosaccharide were labeled with paramagnetic Mn(II) under mild conditions. ATR-FTIR confirmed the successful conjugation of DOTA chelators to the sugar backbone. The conjugates were further characterized by DLS, ICP-MS, and FPLC. In vitro relaxivity was measured at high field strength to evaluate MRI performance. In vivo contrast efficacy was first assessed using in ovo MRI in chicken embryos and subsequently evaluated by biodistribution studies in nude mice.
Results
In vitro relaxivity studies demonstrated higher signal enhancement of the poly-/oligosaccharide-DOTA-Mn(II) conjugates compared with MnCl2 and the clinical agent gadoteridol (ProHance®). In ovo MRI showed persistent vascular enhancement up to 120 min, while in nude mice, contrast enhancement was observed in the liver, kidneys, and gallbladder 40 min post-injection.
Conclusions
Mn(II)-tagged sugar-based imaging probes may offer a promising non-gadolinium alternative to GBCAs, with tunable biodistribution profiles depending on carrier molecular weight.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna & General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Aust…
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Waehringer Strasse 42, 1090 Vienna, Austria.
- Department of Nuclear Medicine, TUM Klinikum Rechts Der Isar, Technical University of Munich, 80333 Munich, Germany.
- Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna & General Hospital of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
- Joint Applied Medicinal Radiochemistry Facility, University of Vienna and Medical University of Vienna, 1090 Vienna, Austria.
- Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2 (UZA II), 1090 Vienna, Austria.
ORCID-Profile: Irena Pashkunova-Martic, Joachim Friske, Daniela Prinz, Theresa Balber, Verena Pichler, Thomas H Helbich
Förderung
- FWF Austrian Science Fund
Zitieren
APA
Pashkunova-Martic, I., Friske, J., Bartsch, S. J., Prinz, D., Balber, T., Pichler, V., Baurecht, D., Keppler, B. K., & Helbich, T. H. (2026). Mn(II)-Tagged DOTA-Modified Sugar-Based Biopolymers as Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging. Pharmaceutics, 18(5), 530. https://doi.org/10.3390/pharmaceutics18050530
Vancouver
Pashkunova-Martic I, Friske J, Bartsch SJ, Prinz D, Balber T, Pichler V, et al. Mn(II)-Tagged DOTA-Modified Sugar-Based Biopolymers as Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging. Pharmaceutics. 2026;18(5):530. doi:10.3390/pharmaceutics18050530
BibTeX
@article{PashkunovaMartic2026,
author = {Pashkunova-Martic, Irena and Friske, Joachim and Bartsch, Silvester J and Prinz, Daniela and Balber, Theresa and Pichler, Verena and Baurecht, Dieter and Keppler, Bernhard K and Helbich, Thomas H},
title = {Mn(II)-Tagged DOTA-Modified Sugar-Based Biopolymers as Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {5},
pages = {530},
doi = {10.3390/pharmaceutics18050530}
}
EUVIMED